Pharmaceutical composition comprising FOXM1 inhibitor and immune checkpoint inhibitor for the prevention or treatment of cancer
A pharmaceutical composition combining a FOXM1 inhibitor with an immune checkpoint inhibitor addresses the limitations of current ICIs by reducing PD-L1 expression and enhancing cancer treatment efficacy through tumor inhibition and apoptosis induction.
Patent Information
- Application Number
- KR1020220114268
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-06-16
- Filing Date
- 2022-09-08
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2042-09-08
AI Technical Summary
Current immune checkpoint inhibitors (ICIs) for cancer treatment, such as anti-PD-1 or anti-PD-L1 antibodies, are costly, have immune-related side effects, and are limited in treating large tumors or rapid tumor growth, necessitating a new strategy to enhance therapeutic efficacy.
A pharmaceutical composition combining a FOXM1 inhibitor, such as thiostreptone (TST), with an immune checkpoint inhibitor to reduce PD-L1 expression and inhibit tumor cell proliferation, potentially using a liposome delivery system for hydrophobic compounds.
The combination effectively inhibits tumor growth, reduces cancer cell proliferation, and induces apoptosis, offering a safer and more effective cancer treatment with reduced side effects.
Smart Images

Figure 112022094958968-PAT00064_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer comprising a FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients. Background Technology
[0003] Lung cancer is the second most common cancer in the world after breast cancer, and despite significant advancements in cancer treatment technology, it still ranks first in mortality among all cancers. Non-small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancer patients, and while immune cells infiltrate many NSCLC tissues, cytotoxic T lymphocytes within the tumor tissue are known to be functionally suppressed by various mechanisms, including the abnormal overexpression of immune checkpoint proteins utilized by tumor cells.
[0004] Immune checkpoint inhibitors (ICIs) are a form of cancer immunotherapy that blocks proteins called immune checkpoints, which are expressed on immune cells such as T cells and on cancer cells. Immunotherapy using immune checkpoint inhibitors has recently been significantly improving therapeutic efficacy in various types of cancer, including lung cancer. PD-L1 (Programmed Cell Death-ligand-1) is encoded by the CD274 gene and is an important immune checkpoint molecule that mediates the interaction between cancer cells and tumor-infiltrating T cells. PD-1 is expressed on the surface of T cells, while PD-L1 is expressed in normal tissues to suppress self-aggression by the immune system. However, PD-L1 overexpressed on the surface of cancer cells enables them to evade attacks by immune cells. Therefore, ICIs, such as anti-PD-1 or anti-PD-L1 antibodies that inhibit the interaction between PD-1 and PD-L1, can enhance the therapeutic efficacy of cancers like lung cancer by reactivating immune cell attacks on cancer cells. However, the high cost of ICI therapy not only places a significant financial burden on cancer patients but has also been reported to cause various immune-related side effects, including cardiac complications, in non-target organs. Furthermore, it has been reported that the therapeutic effect of ICIs is limited in cases of large tumors or rapid tumor growth. Consequently, there is a need to develop new strategies or treatments to address these issues associated with ICIs.
[0005] Forkhead box protein M1 (FOXM1) is a key protein that regulates various processes associated with lung cancer tumorigenesis, including cell cycle progression, anticancer resistance, and metastasis. The function of FOXM1 is attributed in part to its ability to translocate to the nucleus via various forkhead or DNA-binding domains and bind to regulatory regions of multiple target genes, which is crucial for the survival of cancer cells. Compounds such as thiostreptone (TST), thiomycin A, RCM-1 (Robert Costa Memorial drug-1), and FDI-6 (Forkhead domain inhibitor-6) have been identified as FOXM1 inhibitors. Among these, TST, a natural thiazole antibiotic isolated from Streptomyces azureus, inhibits the interaction between the forkhead domain of FOXM1 and target DNA. Furthermore, TST has been used to treat mastitis caused by Gram-negative bacteria and has been reported to be active against breast cancer.
[0006] Against this backdrop, the inventors completed the present invention by confirming through research using a FOXM1 inhibitor that the inhibitor not only significantly reduces PD-L1 expression but also inhibits the proliferation of tumor cells, thereby confirming that it has an effect of preventing or treating cancer. Prior art literature
[0008] Molecular Oncology 13 (2019) 873-893. The problem to be solved
[0009] The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cancer comprising a FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients.
[0010] Another objective of the present invention is to provide an anticancer adjuvant comprising a FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients. means of solving the problem
[0012] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application should not be considered limited by the specific descriptions provided below.
[0013] In one embodiment for achieving the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of cancer comprising a FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients.
[0014] In the present invention, 'FOXM1 (Forkhead box protein M1)' is a protein belonging to the FOX family of transcription factors, encoded by the FOXM1 gene, and is known to play an important role in cell cycle progression.
[0015] In the present invention, 'FOXM1 inhibitor' is a substance that inhibits FOXM1, and any substance that inhibits or reduces the expression of FOXM1 may be used without limitation. Specifically, it may be a thiazolidinedione, diarylheptanoid, RCM-1, thiostreptone, honokiol, FDI-6, siomycin A, monensin, FOXM1 aptamer (FOXM1 apt), peptide 9R-P201, or a pharmaceutically acceptable salt thereof.
[0016] The above thiazolidinedione compound is a type of heterocyclic compound composed of a 5-membered C3NS ring that is reported to be a drug that can be used to treat type 2 diabetes by lowering blood glucose levels, and may be, for example, TFI-1 to TFI-10, preferably TFI-10, but is not limited thereto.
[0017] The above TFI-10 compound is a thiazolidinedione forkhead domain inhibitor and refers to a substance having the structure of Chemical Formula 1 as a backbone, (5Z)-5-[(3-methoxy-4-{[4-(trifluoromethyl)phenoxy]methyl}phenyl)methylidene]-1,3-thiazolidine-2,4-dione ((5Z)-5-[(3-methoxy-4-{[4-(trifluoromethyl)phenoxy]methyl}phenyl)methylidene]-1,3-thiazolidine-2,4-dione).
[0018] [Chemical Formula 1]
[0019]
[0020] The above-mentioned diarylheptanoid is a collective term for secondary metabolites of plants that consist of two aromatic rings (aryl groups) connected by a 7-carbon chain (heptane) and have various substituents, and are known to have antioxidant activity.
[0021] The above RCM-1 refers to a substance having the structure of Chemical Formula 2, which is a FOXM1 inhibitor known to block nuclear localization and increase the proteasome degradation of FOXM1.
[0022] [Chemical Formula 2]
[0023]
[0024] The above thiostrepton refers to a natural cyclic oligopeptide antibiotic of the thiopeptide family derived from various Streptomyces strains such as Streptomyces azureus and Streptomyces laurentii, and means a substance having the structure of Chemical Formula 3.
[0025] [Chemical Formula 3]
[0026]
[0027] The above-mentioned honokiol is a lignan isolated from the bark, seeds, and leaves of trees belonging to the genus Magnolia, and is known to have high bioavailability as it can easily pass through the blood-brain barrier and the blood-cerebrospinal fluid barrier, and refers to a substance having the structure of Chemical Formula 4.
[0028] [Chemical Formula 4]
[0029]
[0030] The above FDI-6 refers to a substance having the structure of Chemical Formula 5, which is a FOXM1 inhibitor that directly binds to the FOXM1 protein and induces transcriptional downregulation.
[0031] [Chemical Formula 5]
[0032]
[0033] The above Siomycin A refers to a substance having the structure of Chemical Formula 6, which is a thiazole antibiotic reported to downregulate mRNA and protein expression as well as the transcriptional activity of FOXM1.
[0034] [Chemical Formula 6]
[0035]
[0036] The above monensin is also called monensic acid, monensin A, monensina, monensinum, or rumensin, and is a polyether antibiotic isolated from Streptomyces cinnamonensis, and refers to a substance having the structure of chemical formula 7.
[0037] [Chemical Formula 7]
[0038]
[0039] The above FOXM1 aptamer (FOXM1 apt) is a general term for FOXM1-specific aptamers that target the FOXM1 DNA binding domain, and may consist of, for example, the sequence of SEQ ID NO. 9, but is not limited thereto.
[0040] The above-mentioned peptide 9R-P201 is a peptide reported to inhibit the survival, proliferation, and migration of cancer cells and induce apoptosis by downregulating FOXM1 expression, and is a peptide substance in which nine arginines are conjugated to P201 (peptide) (Jian Cui et al. Int J Pept Res Ther 20, 447-456(2014) ) It means.
[0041] The FOXM1 inhibitor of the present invention may, for example, reduce the level of the FOXM1 gene or protein, or reduce the nuclear translocation of FOXM1.
[0042] In the present invention, the FOXM1 inhibitor may be obtained from biological sources known in the art, or may be chemically synthesized or commercially available.
[0043] In the present invention, the FOXM1 inhibitor comprises a pharmaceutically or food-grade acceptable salt form within the range having the same efficacy. Such salts are pharmaceutically or food-grade acceptable salts and may be basic salts or acidic salts; basic salts may be used in the form of either organic basic salts or inorganic basic salts and may be selected from the group consisting of sodium salts, potassium salts, calcium salts, lithium salts, magnesium salts, cesium salts, aluminum salts, ammonium salts, triethylaminium salts, and pyridinium salts.
[0044] As for the types of such salts, acid addition salts formed by free acids are useful as acid salts. Inorganic and organic acids may be used as free acids; inorganic acids may include hydrochloric acid, bromic acid, sulfuric acid, sulfite, phosphoric acid, diphosphate, nitric acid, etc., and organic acids may include citric acid, acetic acid, maleic acid, malic acid, fumaric acid, glutonic acid, methanesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, oxalic acid, malonic acid, glutaric acid, acetic acid, glyconic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, emvonic acid, glutamic acid, citric acid, aspartic acid, stearic acid, etc., but are not limited thereto and may include all salts formed using various inorganic and organic acids commonly used in the industry.
[0045] In the present invention, an 'immune checkpoint inhibitor' refers to a drug that blocks proteins called immune checkpoints expressed in some immune cells, such as T cells, and cancer cells as a form of cancer immunotherapy. Specifically, it may be, but is not limited to, a PD-L1 inhibitor, an anti-PD-L1 antibody, a PD-1 inhibitor, an anti-PD-1 antibody, a CTLA inhibitor, an anti-CTLA4 antibody, an anti-PD-L2 antibody, an LTF2 regulatory antibody, an anti-LAG3 antibody, an anti-A2aR antibody, an anti-TIGIT antibody, an anti-TIM-3 antibody, an anti-B7-H3 antibody, an anti-B7-H4 antibody, an anti-VISTA antibody, an anti-CD47 antibody, an anti-BTLA antibody, an anti-KIR antibody, an anti-IDO antibody, or an anti-4-1BB antibody.
[0046] In the present invention, "active ingredient" refers to a component that exhibits the intended activity alone, or can exhibit activity together with a carrier that is inactive itself.
[0047] In the present invention, 'cancer (or tumor)' does not distinguish between primary cancer or metastatic cancer and may be a solid tumor or a blood cancer. Specifically, the cancer may be lung cancer, pancreatic cancer, pharyngeal cancer, laryngeal cancer, esophageal cancer, stomach cancer, duodenal cancer, small intestine cancer, colorectal cancer, colon cancer, rectal cancer, breast cancer, ovarian cancer, prostate cancer, liver cancer, thyroid cancer, kidney cancer, uterine cancer, brain tumor, skin cancer, melanoma, malignant bone tumor, bladder cancer, or blood cancer, but is not limited thereto. More specifically, the cancer may be lung cancer or colorectal cancer.
[0048] The term "prevention" in this invention refers to any act of suppressing or delaying the occurrence of cancer by administering the composition of this invention; "improvement" refers to exhibiting an effect of delaying the progression of cancer or alleviating cancer symptoms by applying the composition of this invention; and "treatment" refers to any act of beneficially altering the condition, such as completely suppressing the progression of cancer or improving symptoms, by administering the composition of this invention.
[0049] The composition of the present invention has, for example, efficacy in preventing, improving, or treating cancer by reducing or inhibiting the expression of PD-L1, thereby reducing the proliferation and survival of cancer cells and inducing an increase in apoptosis.
[0050] The above decrease in PD-L1 expression may mean a decrease in the level of PD-L1 protein expression at the cell membrane.
[0051] As one embodiment for achieving the above objective, when the FOXM1 inhibitor of the present invention is a hydrophobic compound with low solubility in water, it may be provided in a form supported on a liposome as a system for effectively delivering the hydrophobic compound to a tumor, specifically, it may be supported on the surface, interior, or phospholipid bilayer of a liposome, but is not limited thereto.
[0052] The above liposome refers to a double-layer membrane structure composed of phospholipids, and preferably may refer to a micelle structure.
[0053] The phospholipids constituting the above liposome are 1,2-dioleoyl-sn-glycero-2-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000](DSPE-PEG2000), cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methyl(polyethylene glycol)-5000], 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methyl(polyethylene glycol)-5000] ammonium salt, dioleoyl phosphatidylcholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, It may be at least one selected from the group consisting of dipalmitoylphosphatidylcholine and cholesteryl hemisuccinate, but is not necessarily limited thereto.
[0054] There are no specific restrictions on the content ratio of phospholipids constituting the above liposome, and the ratio can be freely set considering the size of the liposome to be manufactured.
[0055] As one embodiment for achieving the above objective, the liposome of the present invention may be composed of DOPC, cholesterol, and DSPE-PEG2000, and specifically, the molar ratio of each component may be 5 to 15, 3 to 13, and 1 to 12, but is not limited thereto.
[0056] The pharmaceutical composition of the present invention may be for the combined administration of a FOXM1 inhibitor and an immune checkpoint inhibitor. Specifically, the pharmaceutical composition may be in the form of a mixture in which the FOXM1 inhibitor and the immune checkpoint inhibitor are mixed, or the FOXM1 inhibitor and the immune checkpoint inhibitor may be formulated separately and administered simultaneously or sequentially, but is not limited thereto.
[0057] When a FOXM1 inhibitor and an immune checkpoint inhibitor are administered in combination, the dosage ratio of the FOXM1 inhibitor and the immune checkpoint inhibitor may be 1:0.01 to 1:1000, specifically 1:0.01 to 1:500, 1:0.05 to 1:300, 1:0.1 to 1:200, or 1:1 to 1:100, and more specifically 1:0.01, 1:0.02, 1:0.03, 1:0.05, 1:0.08, 1:0.1, 1:0.3, 1:0.5, 1:0.7, 1:0.8, 1:1, 1:1.5, 1:2, 1:3, 1:5, 1:7, 1:8, 1:10, 1:25, 1:50, It may be 1:100, 1:200, or 1:500, but is not limited thereto.
[0059] When a liposomal-loaded FOXM1 inhibitor and an immune checkpoint inhibitor are co-administered, the administration concentration ratio of the liposomal-loaded FOXM1 inhibitor and the immune checkpoint inhibitor may be 1:0.01 to 1:1000, specifically 1:0.01 to 1:500, 1:0.05 to 1:300, 1:0.1 to 1:200, or 1:1 to 1:100, and more specifically 1:0.01, 1:0.02, 1:0.03, 1:0.05, 1:0.08, 1:0.1, 1:0.3, 1:0.5, 1:0.7, 1:0.8, 1:1, 1:1.5, 1:2, 1:3, 1:5, 1:7, 1:8, 1:10, It may be 1:25, 1:50, 1:100, 1:200, or 1:500, but is not limited thereto.
[0060] The pharmaceutical composition of the present invention may further comprise pharmaceutically acceptable carriers, excipients, or diluents according to conventional methods. Pharmaceutically acceptable carriers are known in the art according to the route of administration or formulation, and specifically, reference may be made to the pharmacopoeias of each country, including the Korean Pharmacopoeia. Carriers, excipients, and diluents that may be included in the composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, carriers, excipients, and diluents that may be included in the composition of the present invention may be non-natural carriers, but are not limited thereto.
[0061] The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, as well as external preparations, suppositories, or sterile injectable solutions, according to conventional methods. Specifically, when formulating, it may be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, and surfactants that are commonly used. Solid formulations for oral administration include tablets, pills, powders, granules, and capsules, and such solid formulations may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc., with the above compounds. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid formulations for oral administration include suspensions, oral liquids, emulsions, syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Macrogol, Tween 61, cacao gelatin, laurin gelatin, glycerogelatin, etc., may be used. Specific formulations of pharmaceutical compositions are known in the art, and reference may be made to literature such as [Remington's Pharmaceutical Sciences (19th ed. 1995)]. The said literature is considered to be part of this specification.
[0062] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The pharmaceutically effective amount refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause adverse effects. The effective dose level may be determined based on factors including the patient's health status, type and severity of the disease, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field. The dosage and frequency of administration do not limit the scope of the present invention in any way.
[0063] The pharmaceutical composition of the present invention can be administered to mammals such as rats, dogs, cats, cattle, horses, pigs, and humans through various routes.
[0064] The pharmaceutical composition of the present invention can be applied to any formulation containing a FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients, and can be prepared as an oral or parenteral formulation. Specifically, there are no restrictions on the method of administration, but it includes forms suitable for oral, rectal, nasal, topical (including the cheek and under the tongue), subcutaneous, vaginal, or parenteral (including intramuscular, subcutaneous, and intravenous) administration, or forms suitable for administration by inhalation or infusion.
[0066] As one embodiment for achieving the above objective, the present invention provides an anticancer adjuvant comprising a FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients.
[0067] The above 'FOXM1 inhibitor', 'immune checkpoint inhibitor', 'active ingredient', and 'cancer' are as described above.
[0068] The anticancer adjuvant of the present invention refers to any form intended to enhance the anticancer effect of an anticancer drug or to suppress or improve the side effects of an anticancer drug. The anticancer adjuvant of the present invention may be administered in combination with various types of anticancer drugs or anticancer adjuvants; when administered in combination, an equivalent level of anticancer therapeutic effect can be achieved even when the anticancer drug is administered at a lower dose than the conventional dosage, thereby enabling safer anticancer treatment.
[0069] The route of administration of the above anticancer adjuvant may be administered through any general route as long as it can reach the target tissue. Depending on the purpose, the anticancer adjuvant of the present invention may be suitable for oral, rectal, nasal, topical (including the cheek and under the tongue), subcutaneous, vaginal, or parenteral (including intramuscular, subcutaneous, and intravenous) administration, or may be administered by inhalation or insufflation, but is not limited thereto. Additionally, the above anticancer adjuvant may be administered by any device capable of delivering the active substance to the target cells.
[0070] The anticancer adjuvant of the present invention may preferably be formulated as an anticancer adjuvant by including one or more pharmaceutically acceptable carriers in addition to the active ingredient for administration. Carriers, excipients, or diluents that may be included in the anticancer treatment adjuvant of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Effects of the invention
[0072] The pharmaceutical composition comprising the FOXM1 inhibitor and the immune checkpoint inhibitor of the present invention effectively inhibits tumor growth and induces apoptosis compared to the FOXM1 inhibitor or the immune checkpoint inhibitor alone, thereby exhibiting effects of preventing, improving, or treating cancer; thus, it can be usefully used as a preventive or therapeutic agent for such cancer. Brief explanation of the drawing
[0074] Figure 1 shows the results confirming that PD-L1 is downregulated in FOXM1-knockdown lung adenocarcinoma (LUAD) cell lines. Figure 1a shows the overall survival curves for lung adenocarcinoma patients with or without alteration (red line) in the expression of FOXM1 and PD-L1 (blue line). Figure 1b shows the results of immunohistochemical analysis on the expression levels of FOXM1 and PD-L1 in human lung cancer tissue and normal lung tissue. Figures 1c and 1d show the results of RNA-seq and gene ontology functional activation analysis performed on H1299 and PC9 cells transfected with siFOXM1. Figures 1e, 1f, and 1g show the results of semi-quantitative PCR confirming the expression levels of FOXM1 and CD274 (PD-L1) in H1299 and PC9 cells following FOXM1-knockdown, overexpression, or thiostreptone (TST) treatment. Figure 2 shows the results of confirming the association between thiostreptone (TST)-mediated downregulation of FOXM1 and reduced cell proliferation, reduced survival, and increased apoptosis. The apoptotic effect of FOXM1 reduction following transfection with siFOXM1 or treatment with thiostreptone (5 μM) was confirmed (Figures 2a and 2b), FACS analysis of DNA content by PI staining (Figures 2c and 2d), and FACS analysis of apoptotic cells after staining with Annexin V and PI (Figures 2e and 2f) were performed. Figures 2g and 2h show the results of confirming the protein expression levels of FOXM1, c-MYC, cyclin B1, cyclin E1, and cyclin D1 in cells treated with siFOXM1 knockdown or thiostreptone. Figure 3 shows the results confirming that the downregulation of FOXM1 by thiostreptone (TST) is associated with reduced PD-L1 expression in the cell membrane. These are the fluorescence imaging results for H1299 cells (Figures 3a to 3c) and PC9 cells (Figures 3b to 3d) treated with siFOXM1 knockdown or thiostreptone. Figures 3e and 3f show the results of quantitative analysis of the PD-L1 fluorescence signal in the fluorescence images. Figure 4 shows the results confirming that the nuclear translocation of FOXM1 is inhibited by thiostreptone (TST) treatment. Changes in FOXM1 protein levels in the cytoplasmic and nuclear fractions of H1299 cells and PC9 cells treated with FOXM1-knockdown, overexpression, or TST were evaluated by Western blotting (Figures 4a and 4b) and fluorescence imaging (Figures 4c to 4f). Figure 5 shows the results of confirming, by immunoblot analysis (Figures 5a and 5b) or fluorescence imaging (Figures 5c to 5f), that reduced PD-L1 expression is restored by the overexpression of FOXM1. Figure 6 is the result confirming that FOXM1 binds to the promoter of the gene encoding PD-L1 and mediates the expression of PD-L1. Figure 7 shows the results confirming that thiostreptone (TST) inhibits in vivo tumor growth and PD-L1 expression. Figures 7a to 7c show the timeline of tumor formation and thiostreptone administration performed on BALB / c mice, along with the corresponding tumor volume, body weight, and expression levels. Figure 7d shows the results of analyzing blood biochemical data from control mice and thiostreptone-treated mice. Figure 7e shows the results of performing hematoxylin & eosin (H&E) staining and TUNEL staining on tissue sections of the liver, kidney, and spleen of control mice and thiostreptone-treated mice, and analyzing the rate of apoptosis in these normal tissues. Figure 8 shows the results confirming the antitumor effects of the combination of thiostreptone (TST) and anti-4-1BB antibody in a syngeneic Lewis lung cancer (LLC-1) animal model. Figures 8a to 8c show the timeline of tumor formation and drug administration performed on C57BL / 6 mice, along with the results confirming the corresponding tumor volume and body weight. Figures 8d and 8e show the results of analyzing apoptosis by performing TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) analysis on the mice of Figure 8a, and CD3 + This is the result of confirming T cell levels using immunohistochemistry. Figure 9 shows the results confirming the synergistic anti-tumor effect when thyrostreptone (TST) and immune checkpoint inhibitors are administered in combination in a syngeneic Lewis lung cancer (LLC-1) animal model using C57BL / 6 mice. Figure 9a shows the timeline of tumor formation and drug administration in the animal model. Figure 9b shows the results confirming the synergistic anti-tumor effect when thyrostreptone (TST) and anti-4-1BB antibody are administered in combination compared to when they are administered alone. Figure 8c shows the results confirming the synergistic anti-tumor effect when thyrostreptone (TST) and anti-PD-1 antibody are administered in combination compared to when they are administered alone. Figure 10 shows the results of confirming the expression of FOXM1 and PD-L1 in human colorectal cancer cell lines treated with thiostrepton (TST) by immunoblotting analysis. Figure 11 shows the results confirming the effects of thiostrepton (TST) treatment on MC38 colorectal cancer cells regarding the inhibition of PD-L1 expression and the increase in cancer cell death. Figure 11a shows the results of immunoblotting analysis confirming that FOM1 and PD-L1 expression decreased in a concentration-dependent manner upon thiostrepton (TST) treatment. Figure 11b shows the results of fluorescence imaging analysis confirming that PD-L1 expression on the surface of cancer cells decreased in a concentration-dependent manner upon thiostrepton (TST) treatment. Figure 11c shows data on cell viability according to the concentration of thiostrepton (TST) treatment in MC38 cancer cells. Figure 11d shows data on cell viability according to the concentration of thiostrepton (TST) treatment in normal human primary coronary smooth muscle cells (SMC). Figure 11e shows the results of analyzing the cell death rate of MC38 cells in the control group and the thiostrepton (TST) treatment group using a flow cytometer. Figure 12 shows the results of confirming the characteristics of thiostreptone-loaded liposomes (ThioLipo), Figure 12a shows the chemical structure of thiostreptone (TST), and Figures 12b and 12c show the results of measuring the size distribution of ThioLipos in an aqueous solution and transmission electron microscope (TEM) images. Figure 12d shows the results of evaluating the stability of ThioLipos by measuring the change in size distribution over time. Figure 13 shows the results of analyzing changes in blood concentration over time after intravenously administering free thiostreptone (TST) and ThioLipo at equal doses. Figure 14 shows the results confirming the anti-tumor synergistic effect of the combined administration of ThioLipos and immune checkpoint inhibitors in a winter colorectal cancer model. Figure 14a shows the timeline of the administration of immune checkpoint inhibitors and ThioLipos to mice, and Figure 14b shows the tumor growth curves for the mice in Figure 14a when ThioLipos and anti-4-1BB antibody were administered alone or in combination, or when ThioLipos and anti-PD-1 antibody were administered alone or in combination. Figure 14c shows the tumor growth curves of individual mice for each treatment group in Figure 14b. Figure 15 shows the results of confirming the expression of TUNEL, CD3, and PD-L1 by performing tissue immunostaining on tumor sections of mice administered ThioLipo and immune checkpoint inhibitors alone or in combination, and the results of quantitative analysis. Figure 16 confirms that no side effects occurred when ThioLipo and immune checkpoint inhibitors were administered alone or in combination. Figure 16a shows the results of TUNEL staining on sections of major organs (heart, kidney, liver, lung, and spleen), and no histopathological changes or increased apoptosis of normal cells were observed. Figure 16b shows the results of analyzing blood biochemical data from mice, and no side effects were observed. Figure 17 shows the results confirming that FOXM1 and PD-L1 are downregulated by FDI-6 in lung adenocarcinoma (LUAD) and colorectal cancer cell lines. Figure 17a shows the results of immunoblotting observing that the expression of FOXM1 and PD-L1 decreased simultaneously in proportion to the concentration of FDI-6 treated in lung cancer cell lines. Figure 17b shows the results of immunoblotting observing that the expression of FOXM1 and PD-L1 decreased simultaneously in proportion to the concentration of FDI-6 treated in colorectal cancer cell lines. Figure 18 shows the results confirming that the expression of FOXM1 and PD-L1 is downregulated by RCM1 treatment in lung cancer cells, colorectal cancer cells, and brain tumor cells. Figure 18a shows the results of immunoblotting confirming that the expression of both FOXM1 and PD-L1 is inhibited in lung cancer, colorectal cancer, and brain tumor cell lines in proportion to the RCM1 treatment concentration. Figure 18b shows the results of fluorescence imaging confirming that PD-L1 expression is reduced on the surface of cancer cells when human lung cancer cell lines are treated with RCM1. Specific details for implementing the invention
[0075] The present invention will be explained in more detail below through the following examples. However, these examples are intended to illustrate the invention and the scope of the invention is not limited to these examples.
[0077] Example 1: Confirmation of the association between FOXM1 and PD-L1 expression
[0078] 1.1. Information Analysis of FOXM1 and PD-L1 in Lung Adenocarcinoma (LUAD)
[0079] (1) Data set for information analysis of FOXM1 and PD-L1 in lung adenocarcinoma (LUAD)
[0080] To determine the roles of FOXM1 and PD-L1 in the prognosis of LUAD, the TCGA (Cancer Genome Atlas) LUAD Firehose Legacy (n = 586), available on cBioPortal for cancer genome open access resources, was used.
[0081] (2) Geneset Concentration Analysis (GEA)
[0082] DEGs were listed in response to siFOXM1 knockdown, and genes significantly downregulated (less than 0.5-fold between NC siRNA and siFOXM1 knockdown H1299 and PC9 cells) were applied to GSEA using the Enrichr database.
[0084] 1.2. Cell Culture and Transfection
[0085] H1299 and PC9 cells purchased from ATCC (Manassas, VA, USA) were cultured in RPMI-1640 medium (#10-040-CV; Corning, New York, NY, USA) supplemented with 10% human serum albumin (#35-010-CV; Corning) and a penicillin-streptomycin antibiotic cocktail (#15240062; Thermo Fisher Scientific, Waltham, MA, USA) at 37°C and 5% CO2.
[0086] H1299 and PC9 LUAD cells were transfected with 5 nM negative control (NC) or FOXM1 siRNA (siFOXM1) (QIAGEN, Hilden, Germany) using Lipofectamine RNAiMAX (#13778150; Thermo Fisher Scientific). H1299 and PC9 cells were transfected with human FOXM1 isoform b (pFLAG-FOXM1)-expressing plasmid or empty vector (pFLAG-CMV; mock) using Lipofectamine 2000 reagent (#11668019; Thermo Fisher Scientific) according to the manufacturer's instructions.
[0088] 1.3. Reverse Transcription and Semi-Quantitative PCR
[0089] Total RNA was extracted and purified using the RNeasy kit (#74004; QIAGEN) according to the manufacturer's protocol. mRNA reverse transcription was performed using the PrimeScript 1st Strand cDNA Synthesis Kit (#6110A; TaKaRa Bio, Otsu, Japan). Quantitative PCR was performed using primers specific to the CD274 and FOXM1 genes designed using Primer 3 software. The β-actin gene was used as an internal control to normalize target gene expression. The primer pair sequences used in this invention are listed in Table 1.
[0090] [Table 1]
[0091]
[0093] 1.4. Confirmation of the association between FOXM1 and PD-L1 expression in lung cancer cells
[0094] To investigate the clinical associations of FOXM1 and PD-L1 in adenocarcinoma patients, survival curves for lung adenocarcinoma (LUAD) were analyzed from the cBioPortal TCGA (The Cancer Genome Atlas) dataset. The 70 patients with higher expression of FOXM1 and PD-L1 had a lower median overall survival than the 443 patients with no change in FOXM1 and PD-L1 expression (31.21 months vs. 50.20 months, p = 8.716 × 10⁻¹⁰). -4 , Fig. 1a).
[0095] In addition, to determine whether FOXM1 is associated with poor prognosis in LUAD patients as a putative transcription factor (TF) regulating PD-L1 expression, lung cancer tissue and corresponding normal tissue were immunostained with antibodies against FOXM1 and PD-L1 to compare the expression of FOXM1 and PD-L1. As a result, FOXM1 and PD-L1 were upregulated in LUAD tissue compared to adjacent normal tissue (Fig. 1b).
[0096] RNA-seq analysis was performed on H1299 and PC9 cells that underwent FOXM1 knockdown by siRNA. As a result, among the 67 differentially expressed genes (DEGs) expressed at levels below 0.5 in the two cell lines, the CD274 gene encoding PD-L1 was presumed to be a target of FOXM1 (Fig. 1c). To confirm the biological functions of the downregulated genes after FOXM1 knockdown in H1299 and PC9 cells, gene set enrichment analysis (GSEA) was performed on the downregulated genes (a total of 67) using the Enrichr database. Positive transcriptional regulation and cell cycle regulation by RNA polymerase II were significantly activated in the target genes (Fig. 1d), suggesting that FOXM1 may also contribute to the regulation of CD274. The encoded PD-L1 protein plays a crucial role in immune evasion in lung cancer cells. After knocking down FOXM1 with siRNA, PD-L1 expression was checked, and PD-L1 transcription levels were significantly reduced in both cell lines (Fig. 1e).
[0097] Additionally, PD-L1 transcription levels were evaluated after overexpressing FOXM1 using pFLAG-FOXM1 isoform b, a major isoform expressed under physiological conditions. As a result, overexpression of FOXM1 significantly increased PD-L1 mRNA expression in H1299 and PC9 cells (Fig. 1f).
[0098] The potential effects of FOXM1 on PD-L1 expression in NSCLC cells were evaluated using FOXM1 inhibition strategies other than siRNA knockdown. Several FOXM1 inhibitors, including the natural product TST, were tested in H1299 and PC9 cells, and among them, TST was the most efficient inhibitor, significantly reducing FOXM1 levels.
[0099] To induce an increase in PD-L1 expression, PD-L1 transcription levels were analyzed in cells treated with TST in the presence of IFN-γ, and the results showed that the decrease in FOXM1 induced by TST caused a concentration-dependent decrease in PD-L1 mRNA expression in both cell lines (Fig. 1g).
[0101] Example 2: Confirmation of effects on cells following FOXM1 inhibition
[0102] 2.1. Cell Analysis Methods
[0103] (1) Cell proliferation analysis
[0104] H1299 and PC9 cells were proliferated in 96-well plates and treated with 5 μM TST or transfected with siFOXM1 at a density of 3,000 cells / well in 6-well plates. Cell proliferation was recorded at specified times with the addition of 4-[3-(4-iodophenyl)-2-(4-nitro-phenyl)-2H-5-tetrazolio]-1,3-benzenesulfonate] (WST-1, #MK400, TaKaRa Bio) for 2 hours at 37 °C, and absorbance was measured at 450 nm. All experiments were performed in quadruples.
[0105] (2) Analysis of cell cycle distribution
[0106] Both H1299 and PC9 cells were enzymatically dissociated using TrypLE (#12605-010; Thermo Fisher Scientific), collected by centrifugation at 2,000 xg for 2 minutes, resuspended in PBS, fixed with 70% ethanol, and incubated overnight at 4°C. The fixed cells were pelleted, washed twice with PBS, resuspended in FxCycle PI (propidium iodide) / RNase staining solution (#F10797; Thermo Fisher Scientific), and incubated in the dark at 37°C for 30 minutes. Flow cytometry was performed using a FACS-LSR Fortessa flow cytometer (BD Biosciences, Santa Clara, CA, USA).
[0107] (3) Apoptotic cell death analysis (Annexin V / PI staining)
[0108] H1299 and PC9 cells (1 x 10⁶ 5 Cells were cultured in 6-well plates and transfected with siFOXM1 or NC siRNA, or treated with 5 μM TST or dimethyl sulfoxide (DMSO), after which the cells were stained using the fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection Kit I (#556547; BD Biosciences). Cells were analyzed within 1 hour to minimize adverse effects from staining, and flow cytometry was performed using a FACSVerse cell analyzer (BD Biosciences).
[0110] 2.2. Inhibition of Cell Growth and Induction of Apoptosis by FOXM1 Inhibition
[0111] To confirm the effects of FOXM1 on cell proliferation and survival in NSCLCs, time-course experiments were conducted for 24, 48, and 72 hours. As a result, cell proliferation decreased in a time-dependent manner in both cell lines in response to siRNA-mediated knockdown and 5 μM TST treatment (Figs. 2a and 2b). Additionally, analysis of protein content using flow cytometry on cells treated with siFOXM1 or TST revealed that FOXM1 knockdown by siFOXM1 or inhibition by TST increased the sub-G0 / G1 population and decreased the S phase population in a time-dependent manner compared to the negative control (NC) siRNA or dimethyl sulfoxide (DMSO) treatment groups (Figs. 2c and 2d). Both cell lines treated with TST showed an increase in the G2 population with a decrease in the S phase population compared to the DMSO treatment group. Through this, we confirmed that FOXM1 reduction alters cell cycle progression in NSCLC cells and plays a crucial role in the transition between the G1-S and G2-M phases. Additionally, we confirmed that the apoptotic cell population (annexin V / PI positive cells) significantly increased in a time-dependent manner in FOXM1-decreased cells following siRNA or TST treatment (Figures 2e and 2f).
[0112] Western blot analysis further confirmed the effect of reducing FOXM1 expression on c-MYC, cyclin B1, cyclin E1, and cyclin D1 in two cell lines, and the protein levels of c-MYC, cyclin B1, and cyclin D1 were significantly reduced after reducing FOXM1 expression by siRNA or TST treatment (Figs. 2g and 2h).
[0114] 2.3. Downregulation of PD-L1 on Lung Cancer Cell Membranes Following FOXM1 Reduction
[0115] PD-L1 is a transmembrane protein, and immunocytochemistry (ICC) was performed to evaluate whether FOXM1 knockdown by siRNA or TST treatment reduced total PD-L1 protein levels phenotypically at the cell membrane. Additionally, ICC was performed on H1299 and PC9 cells transfected with siFOXM1 or NC siRNA for 72 hours to assess membrane PD-L1 enrichment; the results showed that PD-L1 membrane expression in H1299 control cells was significantly higher than in siFOXM1-transfected cells (Fig. 3a). FOXM1 downregulation reduced PD-L1 expression by 67.4% (Fig. 3e), and siFOXM1-transfected PC9 cells downregulated FOXM1, reducing PD-L1 expression levels by 81.68% (Figs. 3b and 3f).
[0116] Considering that TST treatment in the presence of IFNγ reduces total PD-L1 protein levels in lung cancer cells, the effect of TST on PD-L1 enrichment in cell membranes was investigated, and as a result, IFNγ-boosted (IFNγ(+)) membrane PD-L1 levels were observed in both cell lines (Figs. 3c and 3d). PD-L1 was reduced in the membranes of TST-treated H1299 and PC9 cells (Figs. 3c and 3d), and FOXM1 downregulation reduced PD-L1 levels in H1299 and PC9 cells by 87.23% and 85.82%, respectively, compared to the DMSO control group (Figs. 3e and 3f).
[0118] Example 3: Confirmation of the inhibitory effect of TST on FOXM1
[0119] 3.1. Protein Analysis
[0120] (1) Nucleus cytoplasmic fractionation
[0121] To confirm intracellular protein localization, H1299 and PC9 cell pellets were lysed in Buffer A (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol (DTT), and 0.05% IGEPAL CA-630 (pH 7.9)) for 10 minutes. The Buffer A lysate was centrifuged at 1,000 xg for 10 minutes at 4 °C to collect the nuclear fraction. After removing the cytoplasmic fraction, Buffer B containing 5 mM HEPES, 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, and 26% glycerol (v / v) (pH 7.9) was added to the nuclear fraction and lysed on ice for 30 minutes.
[0122] (2) Immunoblotting analysis of protein expression
[0123] Cells were lysed in RIPA buffer supplemented with a complete mini-protease inhibitor cocktail (#04693124001; Roche, Basel, Switzerland) and stored on ice for 30 minutes. Equal amounts of protein were evenly loaded and analyzed by SDS-PAGE (sulfate-polyacrylamide gel electrophoresis), and transferred to a PVDF (polyvinylidene difluoride) membrane (#IPVH 00010; Millipore, Billerica, MA, USA) at 100 V for 1 hour. Specific primary antibodies against FOXM1 (#sc-271746), cyclin E1 (#sc-481), α-tubulin (#sc-8035), and β-actin (#sc-47778) (Santa Cruz Biotechnology, Texas, USA); Proteins of interest were investigated using PD-L1 (#13684S), cyclin D1 (#2978S), cyclin B1 (#4138S), c-MYC (#5605S), and poly(ADP-ribose) polymerase (PARP, #9542S; Cell Signaling Technology, Beverly, MA, USA). Horseradish-peroxidase conjugated secondary antibodies specific to the primary antibody were used to detect proteins using a pico-enhanced chemiluminescent substrate (#34577; Thermo Fisher Scientific).
[0124] (3) Immunocytochemistry (ICC)
[0125] Cells were fixed in 4% paraformaldehyde (#30525-89-4; FUJIFILM Wako Chemical, Wako, Japan) for 15 minutes and blocked with 1% BSA (bovine serum albumin) in PBS-0.01% Tween-20 (PBS-T) to reduce non-specific antibody binding. Subsequently, cells were incubated overnight with anti-PD-L1 antibody (#14598382; eBioscience, San Diego, CA, USA) diluted 1:200 and anti-FOXM1 antibody (#sc-271746; Santa Cruz Biotechnology) diluted 1:50, followed by incubation for 1 hour with Alexa Fluor 488-labeled secondary antibody (#A11029; Thermo Fisher Scientific). Nuclei were stained with Hoechst 33342. After culture, cells were washed with PBS and mounted on glass slides using Prolong Glass Antifade mounting medium (#P36982; Thermo Fisher Scientific). Confocal microscopy was performed using a Zeiss 730 Meta microscope (Carl Zeiss, Oberkochen, Germany), and analysis was performed using Axiovision software (Carl Zeiss).
[0127] 3.2. Confirmation of the inhibitory effect of TST on the nuclear translocation of FOXM1
[0128] As nuclear translocation of FOXM1 is highlighted as a prominent feature in various cancers, FOXM1 enrichment was investigated in the nuclei of pFLAG-FOXM1-transfected H1299 and PC9 cells, followed by treatment with siFOXM1 knockdown or TST (5 μM) in the presence of IFN-γ (20 ng mL-1). Although FOXM1 is present in both the nucleus and cytoplasm, FOXM1 overexpression increased the nuclear translocation of cytoplasmic FOXM1. Treatment with siFOXM1-mediated FOXM1 inhibition or TST reduced FOXM1 protein levels and nuclear translocation in H1299 and PC9 cells (Figs. 4a and 4b). Compared to mock transfection, FOXM1 overexpression restored FOXM1 levels in H1299 cells by 48.85% and 84.33% upon treatment with siFOXM1 and TST, respectively. The recovery values in PC9 cells were 30.95% and 57.56% for siFOXM1 and TST treatments, respectively. ICC analysis showed that FOXM1 was primarily localized to the nuclei of H1299 cells transfected with pFLAG-FOXM1 and PC9 cells transfected with NC siRNA compared to siFOXM1-transfected cells (Figs. 4c and 4d). Similarly, in H1299 and PC9 cells transfected with pFLAG-FOXM1, FOXM1 expression was primarily localized to the nucleus compared to TST-treated cells in which FOXM1 expression and nuclear translocation were suppressed. pFLAG-FOXM1-mediated FOXM1 overexpression was significantly reduced by siRNA-mediated knockdown to 54.22% (p < 0.01) in H1299 cells and 35% (p < 0.001) in PC9 cells. In TST-treated cells, FOXM1 overexpression was significantly reduced to 63.7% (p<0.05) in H1299 cells and 44% (p<0.01) in PC9 cells.
[0130] Example 4: Elucidation of the regulatory mechanism of PD-L1 expression by FOXM1
[0131] 4.1. Confirmation of PD-L1 Expression Recovery Caused by FOXM1 Overexpression
[0132] The recovery of PD-L1 expression was confirmed by inducing FOXM1 overexpression in FOXM1-knockdown cell lines. Specifically, H1299 and PC9 cells were transfected with NC siRNA or siFOXM1, followed by transfection with pFLAG-FOXM1 or an empty vector for 72 hours. As a result, Western blot analysis and confocal imaging of the cells confirmed that PD-L1 downregulation induced by siFOXM1 was not restored in mock-transfected cells, but was restored in pFLAG-FOXM1-transfected cells. FOXM1 restored PD-L1 expression on the H1299 and PC9 cell membranes to 55.9% and 51.8%, respectively (Figs. 5a, 5c, and 5d). Similarly, when investigating whether reduced PD-L1 expression could be restored in H1299 and PC9 cells treated with TST (5 μM) for 48 hours in the presence of IFNγ, FOXM1 overexpression restored reduced PD-L1 expression in FOXM1 knockdown cells and also restored reduced PD-L1 expression caused by TST treatment in H1299 and PC9 cells. As shown by Western blotting (Fig. 5b) and confocal microscopy (Figs. 5e and 5f), FOXM1 restored PD-L1 expression on the cell membranes of H1299 and PC9 cells to 38.7% and 46%, respectively. In addition, the increase in PD-L1 levels caused by pFLAG-FOXM1 overexpression (mimicking the malignant tumor mass situation) was significantly reduced by siRNA to 52.6% (p<0.05) in H1299 cells and 59.2% (p<0.01) in PC9 cells, and by TST treatment to 41.9% (p <0.01) in H1299 cells and 68.0% (p <0.05) in PC9 cells.Taken together, these results further support the hypothesis that PD-L1 is a downstream target of FOXM1 and is positively regulated by FOXM1, implying that PD-L1 levels can be finely regulated by inhibiting FOXM1.
[0134] 4.2. Confirmation of the mechanism of PD-L1 expression regulation by FOXM1
[0135] (1) Chromatin Immunoprecipitation (ChIP)
[0136] To cross-link proteins to DNA, H1299 and PC9 cells were treated with 0.7% formaldehyde at 37°C for 10 minutes. Cross-linking was quenched by adding glycine to the culture medium at a final concentration of 0.125 M for 5 minutes. Cells were sonicated for 5 minutes with a Bioruptor Next Gen sonicator (Diagenode, Denville, NJ, USA) using a 30-second on / 30-second off cycle to obtain ~500 bp DNA fragments. Unwanted non-specific components were removed by pre-removing sonicated cell lysates containing genomic DNA fragments. ChIP was performed overnight at 4°C using an antibody against FOXM1 (#sc-271746, Santa Cruz Biotechnology), followed by various washing steps, back-cross-linking, and proteolysis with Protease K (#P2308; Sigma-Aldrich, St. Louis, Missouri, USA). Immunoprecipitated DNA fragments were purified using the phenol-chloroform method, and the purified DNA pellet was resuspended in TE buffer (pH 8.0) for use in PCR. Primers that specifically detect the FOXM1 binding region were designed using the Primer3 tool for ChIP-PCR (Table 1).
[0137] (2) Dual-luciferase analysis
[0138] The pGL3 plasmid (#107003; Addgene, Watertown, MA, USA) containing the 2kb promoter of CD274 was from Julian Downward's laboratory (Coelho MA, de Carne Trecesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J, Immunity 2017, 47 The results were obtained from (1083). H1299 and PC9 cells were co-transfected with the pGL3 2kb promoter. Cells containing the CD274 or control pGL3-basic plasmid and the pGL4.70 hRluc renilla luciferase vector (Promega, Madison, WI, USA) were transfected with siFOXM1 or treated with TST in the presence of interferon-gamma (IFNγ). Cells were harvested 48 hours after transfection, and a double luciferase assay was performed according to the manufacturer's protocol (#E1910; Promega). At least four independent biological replicates were performed to obtain reliable results.
[0139] (3) FOXM1 directly binds to the promoter to regulate PD-L1 expression
[0140] To elucidate the mechanism by which FOXM1 induces PD-L1 expression, ChIP-seq data from the ENCODE 3 database accessed via the UCSC Genome Browser (Human assembly Dec 2013, GRCh38 / hg38) were analyzed. In K562 (human immortalized myeloid leukemia cell line), FOXM1 enrichment was identified in the promoter region with a peak signal at approximately 167 bp upstream of the CD274 transcription start site, and the TAAAC FOXM1 common DNA-binding domain (DBD) was detected in two distant regions (-1,988 bp and -2,310 bp) as well as nearby (approx. 142 bp) from the CD274 transcription start site (Fig. 6a).
[0141] Based on these in silico data, the CD274 promoter region of lung cancer cells was hypothesized as a potential target for the FOXM1 transcription factor, and ChIP-PCR analysis was performed using an anti-FOXM1 antibody to exclude the FOXM1-CD274 DNA complex. The flanking CD274 promoter region adjacent to the putative FOXM1 binding site (~167nt) was detected by semi-quantitative PCR in H1299 and PC9 cells, which contrasts with the dramatic decrease in FOXM1 binding to the CD274 promoter observed in siFOXM1-transfected and TST-treated cells, along with their respective controls. In pFLAG-FOXM1-transfected cells, FOXM1 binding to the CD274 promoter was increased compared to mock-transfected cells, indicating that FOXM1 binds directly to the CD274 promoter (Fig. 6b). Therefore, since FOXM1 binds to the promoter and directly regulates PD-L1 transcription, targeting FOXM1 disrupts FOXM1-mediated regulation of PD-L1 expression.
[0142] Additionally, to determine whether the reduction in FOXM1 binding by siRNA or TST treatment significantly reduced CD274 transcriptional activity, a dual-luciferase reporter assay was performed using a CD274 promoter-luciferase construct. Consistent with the ChIP-PCR results, the reduction of FOXM1 by siRNA significantly decreased relative luciferase activity by 40% (p < 0.001) in H1299 cells and 42% (p < 0.01) in PC9 cells (Fig. 6c). Similarly, inhibition of FOXM1 by TST in the presence of IFNγ also significantly reduced CD274 promoter activity, as indicated by a decrease in relative luciferase activity of 53% in H1299 cells (p < 0.001) and 66% in PC9 cells (p < 0.001) (Fig. 6d).
[0143] These results support the conclusion that nuclear FOXM1 translocation positively regulates PD-L1 expression by directly binding to the CD274 promoter in both H1299 and PC9 cell lines. A new model for the FOXM1-mediated regulation of PD-L1 expression in lung cancer has been proposed, in which FOXM1 induced PD-L1 transcriptional activation by regulating PD-L1 expression through direct binding to the CD274 promoter (Fig. 6g). Since PD-L1 upregulation induced by FOXM1 leads to immune evasion in lung tumor cells, targeting FOXM1 using TST, a natural FOXM1 inhibitor that appears to eliminate immune evasion and reduce tumor growth, could be a novel therapeutic strategy for PD-L1-mediated immune evasion in lung cancer cells.
[0145] Example 5: Confirmation of in vivo FOXM1 inhibitory effect
[0146] 5.1. Animal Models
[0147] (1) Xenograft tumor model
[0148] All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the National Cancer Center Research Institute (NCC-21-619). Prior to euthanasia and sacrifice, mice (n = 6) were intraperitoneally injected with TST dissolved in DMSO at a dose of 17 mg / kg every 2 days. Tumor volume and body weight were measured every other day. Tumor volume (V) was AB 2 Calculated as / 2 (A and B are the long diameter and short diameter (mm), respectively). Two days after the final TST injection, all mice were sacrificed, and tumor tissues were collected for immunohistochemistry (IHC) staining of FOXM1 and PD-L1; these tissues were fixed in 10% neutralized formaldehyde and embedded in paraffin blocks. Tissue microarray (TMA) slides were prepared with a diameter of 4 mm per sample and sliced to a thickness of 4 μm to perform IHC with anti-FOXM1 (#20459S) or anti-PD-L1 (#13684S) (Cell Signaling Technology) antibodies. An Autostainer Link48 (Dako, Agilent Technologies, Santa Clara, CA, USA) was used for the analysis.
[0149] IHC staining was performed using anti-rabbit HRP antibody (K4003, EnVision+ HRP Labelled Polymer Anti-Rabbit, Dako, Agilent Technologies, Carpinteria, CA, USA) and 3,3'-diaminobenzidine (DAB) (K3468, DAB+ Chromogen, Dako, Agilent Technologies, Santa Clara, CA, USA) as substrates, and sections were counterstained with hematoxylin (K8008, EnVision FLEX Hematoxylin, Dako, Agilent Technologies Singapore, Singapore). To analyze the in vivo toxicity of the test drug, four xenograft mice from each group were used for serum biochemical analysis (Table 2). On day 9, serum samples were collected from mice in the control and TST treatment groups. Additionally, vital organs (liver, spleen, and kidney) of the mice were collected and sectioned, and H&E staining was performed to monitor histopathological changes. To analyze apoptosis in response to the test drug, TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) analysis (ApopTag Plus Proxidase In Situ kit, EMD Milipore, Temecula, CA, USA) was also performed on the sectioned tissues.
[0150] (2) Synonymous tumor model using murine lung cancer cells LLC-1
[0151] The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of the National Cancer Center Research Institute (NCC-22-675B). Lewis lung carcinoma LLC-1, murine lung cancer cells (5×10⁶ 5 ) was subcutaneously transplanted into 5-week-old C57BL / 6N mice (n=6 per group) (OrientBio, Seoul, Korea) and left for 10 days to reach approximately 150 mm 3Tumors of a certain volume were formed. Then, mice were injected with a dose of 17 mg / kg of TST and a dose of 0.2 mg / mouse of anti-4-1BB antibody at the time points indicated by the black arrows (Day 1, Day 3, Day 5, and Day 7). Tumor volume and body weight of the mice were measured every other day. On Day 9, all mice were sacrificed to collect tumor tissue, which was fixed in formalin, embedded in paraffin, and sectioned for IHC. Additionally, TUNEL analysis was performed on the sectioned tissues to analyze apoptosis in response to TST and anti-4-1BB antibody treatment.
[0152] CD3 in tumor section + T-cell evaluation was performed as described in a previous paper (Huang Y, Lin C, Kao HK, Hung SY, Ko HJ, Huang YC, Chang YL, Chang KP, Cancer Manag Res 2020, 12,8275). CD3 + T cells were detected by an anti-CD3 antibody (ab16669, Abcam, Cambridge, UK) according to the manufacturer's manual. CD3 + The positive signal intensity of T cells was analyzed using computer image analysis with ImageJ software (LOCI, University of Wisconsin), and CD3 + Signal intensity was calculated as the relative ratio of total positive area to total surface area. Pathological images were obtained using the Aperio VERSA slide scanning system (Leica Biosystems Imaging, Vista, CA, USA). At 100X magnification, three independent and intact computer microscope fields of each tissue sample were captured by Aperio Imagescope software (Leica Biosystems Imaging, Vista, CA, USA) and used for the analysis of CD3+ cell signal intensity across the entire microscope field.
[0153] The in vivo synergistic effect between the TST and anti-4-1BB antibody treatment groups was determined by calculating the CDI (Drug Interaction Factor), and CDI values <1, <0.7, =1, and >1 represent synergy, significant synergy, additivity, and antagonism, respectively.
[0155] In all statistical analyses, the difference between groups is χ² 2 It was evaluated using the test and Student's t-test. Statistical significance was set at p < 0.05, and deviations were expressed as standard deviations.
[0157] 5.2. Tumor Growth Inhibition and PD-L1 Expression Regulation by FOXM1 Inhibition
[0158] To investigate the effects of the FOXM1 inhibitor TST on tumor growth and PD-L1 expression in vivo, human H1299 or PC9 cells (5 x 10 6 ) was subcutaneously transplanted into BALB / c nude mice (n = 6 per group). The average size of the xenografted tumor mass was approximately 170 mm 3When the target was reached, TST was intraperitoneally injected into mice at a dose of 17 mg / kg four times every two days (Fig. 7a). Regular monitoring of tumor volume during inhibitor treatment revealed a significant reduction in tumor volume in the TST-treated group compared to the control group. After nine days, no difference in body weight was observed between the two groups (Fig. 7b). Mice were sacrificed two days after the final TST treatment, and tumor tissues were collected, sectioned, and stained to analyze changes in FOXM1 and PD-L1 expression levels. Immunohistochemical analysis demonstrated that FOXM1 and PD-L1 were overexpressed in lung tumors of control mice but significantly downregulated in TST-treated tumors (Fig. 7c). FOXM1 was primarily localized to the nuclei of control tumor cells, whereas it showed faint immunopositivity in the nuclei of TST-treated tumor cells. These results indicated that PD-L1 was positively expressed in the control tumors of H1299 and PC9 xenografts in relation to FOXM1 expression. In contrast, PD-L1 expression was significantly reduced by TST treatment (Fig. 7c).
[0159] Additionally, serum biochemical analysis was performed to evaluate the potential toxicity of TST in vivo. Levels of blood biomarkers did not change significantly in the TST-treated group compared to the DMSO control group (Fig. 7d and Table 2). Furthermore, hematoxylin and eosin (H&E) staining results showed no significant histological changes in vital organs in the TST-treated group (Fig. 7e). TUNEL analysis of tissue sections demonstrated that TST treatment did not affect apoptosis in normal tissues compared to DMSO control tissues (Fig. 7e). Collectively, these results suggest that TST-mediated FOXM1 inhibition can suppress immune evasion and effectively reduce tumor growth.
[0161] [Table 2]
[0162]
[0163] Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; ALP, Alkaline phosphatase; Glu, Glucose; BUN, Blood urea nitrogen; Crea, Creatinine; T-Bill, Total bilirubin; T-chol, Total cholesterol; TG, Triglycerides; TP, Total protein; Alb, Serum albumin; Glo, Serum globulin; A / G ratio, Serum albumin / serum globulin ratio
[0165] Example 6: Confirmation of anti-tumor synergistic effect following combined administration of a FOXM1 inhibitor and an immune checkpoint inhibitor
[0166] To evaluate the therapeutic potential of TST in cancer immunotherapy, an LLC-1 synonymous tumor model reported to be resistant to ICI treatment was used (Fig. 8a). Lewis lung carcinoma (LLC-1) mouse lung cancer cells (5X10 5 ) was subcutaneously injected into C57BL / 6N mice (n=6 per group) at 150 mm for 10 days. 3 Tumors were induced to form at a volume of [amount]. Mice were injected with a dose of 17 mg / kg of TST and a dose of 0.2 mg / mouse of anti-4-1BB antibody on days 1, 3, 5, and 7. When tumor-bearing mice were treated with anti-4-1BB antibody or TST alone, tumor growth was inhibited by 38% and 48%, respectively, compared to the control group (Fig. 8b). In particular, combination therapy with anti-4-1BB antibody and TST inhibited tumor growth by 65% in tumor-bearing mice compared to the control group, demonstrating significantly improved treatment outcomes in tumor growth inhibition (p < 0.001). No difference in body weight was observed between the experimental groups after 9 days (Fig. 8c).
[0167] Next, TUNEL staining of tumor sections was performed on day 9 to investigate apoptosis in the tumors, and the number of apoptotic tumor cells was 1.38-fold and 2.46-fold higher in the anti-4-1BB treated group (p < 0.05) and the TST treated group (p < 0.05), respectively, compared to the control group (Fig. 8D). The combination of TST and anti-4-1BB antibody synergistically increased the number of apoptotic LLC-1 tumor cells by 4.92-fold and 2.76-fold, respectively, compared to the anti-4-1BB antibody treated group (p < 0.001) or the TST treated group (p < 0.001), respectively (CDI = 0.5). Furthermore, immunohistochemical staining for CD3 in tumor sections revealed that CD3 within the tumors of the anti-4-1BB antibody treated (p < 0.05) and TST treated (p < 0.05) groups... + In T cells, a 1.28-fold and 1.32-fold increase was observed compared to the control group, respectively (Fig. 8d). The combination of TST and anti-4-1BB antibody showed that, compared to the anti-4-1BB antibody treatment group (p < 0.001) or the TST treatment group (p < 0.001), intratumoral CD3 + T-cell frequency (CDI = 0.49) was also increased by 2.72-fold and 2.63-fold, respectively (Fig. 8e). These results indicate that the combination treatment of TST and anti-4-1BB antibody has a significant synergistic effect on immunogenicity and antitumor activity. In particular, the combination of TST and anti-4-1BB antibody significantly delayed tumor growth and attracted T cells to the tumor region in an immune-resistant LLC1 lung tumor model. Additionally, smaller tumor size (i.e., ~80 mm²) 3When treatment was initiated, the anti-4-1BB antibody and TST administration groups showed tumor growth inhibition effects of 36.6% and 63.1%, respectively, and the TST and anti-4-1BB antibody combination administration group showed a tumor growth inhibition effect of 78%, indicating that a synergistic (CDI = 0.94) antitumor effect could be obtained through combination treatment (Fig. 9a). In addition, the anti-PD-1 antibody (0.2 mg / mouse) and TST administration groups showed tumor growth inhibition effects of 38.7% and 63.1%, respectively, and the TST and anti-PD-1 antibody combination administration group showed a tumor growth inhibition effect of 78.4%, indicating that a synergistic (CDI = 0.95) antitumor effect could be obtained through combination treatment (Fig. 9b). These results suggest that the application of TST is a clinically significant strategy for inhibiting tumor growth and enhancing the efficacy of immunotherapy when combined with immune checkpoint inhibitors.
[0169] Example 7: Confirmation of the effect of TST on colorectal cancer cell lines
[0170] 7.1. Analysis of Apoptosis, Viability, and Protein Expression
[0171] (1) Reagents and cell cultures used in the experiment
[0172] Dimethyl sulfoxide (DMSO) and TST (Sigma-Aldrich, St. Louis, MO, USA). Amicon centrifugal filter unit (MWCO 50 K, UFC805024, Merck Millipore). Sephadex G25 gel filtration column (PD-10; #17-0851-01, GE Healthcare). Anti-PD-1 (clone: RMP1-14, BP0146) and anti-4-1BB (clone: 17B5, BE0296) antibodies (BioXcell). Anti-CD3 antibody (ab16669, Abcam). Anti-PD-L1 antibody (13684, Cell Signaling Technology).
[0173] Human colorectal cancer cell lines (HCT116, HCT8, and SW480) and human primary coronary smooth muscle cells (SMC) were purchased from the American Type Culture Collection (Manassas, VA, USA), and the MC38 mouse colorectal adenocarcinoma cell line was provided by Dr. Bum-Kyu Choi (National Cancer Center, Goyang, South Korea). MC38 cells were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS and 1% penicillin / streptomycin. SW480 and HCT8 cells were cultured in RPMI (Roswell Park Memorial Institute) medium supplemented with 10% FBS and 1% penicillin / streptomycin. HCT116 cells were maintained in McCoy's 5A medium supplemented with 10% FBS and 1% penicillin / streptomycin. Cells were maintained at 37°C in a humidified incubator with 5% CO2.
[0174] (2) Immunoblotting
[0175] For immunoblotting analysis, protein concentrations were measured using a viscinconinic acid kit (Cat. 23225; Thermo Fisher Scientific, Carlsbad, CA, USA). Proteins were separated by SDS-PAGE electrophoresis. Primary antibodies against FOXM1 (#ab207298, Abcam), PD-L1 (#14-5982-82, Invitrogen), and glyceraldehyde-3-phosphate dehydrogenase (#sc-25778, Santa Cruz Biotechnology) were added, and the samples were incubated overnight at 4°C. After attaching appropriate secondary antibodies conjugated with horseradish peroxidase to the washed membranes, protein bands were detected using a chemiluminescence kit (Thermo Fisher Scientific, Carlsbad, CA, USA).
[0176] (3) Cell death analysis (Annexin V analysis)
[0177] MC38 cells (8.0 x 10⁶ 4 ) was seeded into a 6-well plate and cultured for 24 hours. Cells were treated with TST (5 μM) for 48 hours, harvested, and analyzed via FACS-Verse using the BD FITC Annexin V Apoptosis Detection Kit I (Cat No. 556547; BD Biosciences, San Diego, CA, USA) according to the manufacturer's protocol.
[0178] (4) Cell viability analysis
[0179] MC38 and SMC in a 96-well plate, 3 x 10 3 Cells were cultured at a cell / well density. Cells were treated with various concentrations of TST dissolved in the medium for 48 hours, then WST-1 reagent (MK400; Takara) was added at a concentration of 10 μL / well and cultured for 1 hour, and absorbance was measured at 450 nm for further analysis.
[0180] (5) Analysis of PD-L1 expression according to TST treatment
[0181] To confirm the dose-dependent downregulation of PD-L1 levels by the FOXM1 inhibitor TST, live cell imaging of PD-L1 expression in MC38 cells was performed. MC38 cells were cultured in Lab-Tek II and treated with various concentrations of TST (0, 1, 5, 10 μM) for 48 hours. Subsequently, cells were cultured with an anti-PD-L1 antibody (#14-5982-82; eBioscience, San Diego, CA, USA) and then conjugated with a secondary antibody labeled Alexa Fluor 594 (A21209; Thermo Fisher, Waltham, MA, USA), and cell nuclei were stained with Hoechst33342 dye (Thermo Fisher, Waltham, MA, USA). Cells were washed three times with PBS (pH 7.4, 10 mM, 136 mM NaCl), and the medium was replaced with fresh complete medium. Nuclei (λex 359 nm, λ em 457 nm) and PD-L1 (λ ex 590 nm, λ em Fluorescence images at 618 nm were obtained using a confocal scanning laser microscope (LSM780; Carl Zeiss, Oberkochen, Germany).
[0183] 7.2. Confirmation of the effect of TST on PD-L1 expression in colorectal cancer cells
[0184] Analysis of the effects of TST on PD-L1 expression in human and mouse colon cancer cells revealed that in human colon cancer cells (HCT8, HCT116, and SW480), both FOXM1 and PD-L1 levels were significantly reduced upon treatment with 5 μM TST (Fig. 10). In MC38 mouse colon cancer cells, FOXM1 and PD-L1 expression levels also decreased in a dose-dependent manner after TST treatment (Fig. 11a). Confocal fluorescence images for the immunocytochemical analysis of PD-L1 expression showed strong fluorescence signals on the surface of cancer cells (Fig. 11b). PD-L1 levels within the plasma membrane decreased in a dose-dependent manner after TST treatment. Just as FOXM1 selectively upregulates PD-L1 expression by directly binding to the nuclear PD-L1 promoter, TST clearly reduced PD-L1 expression in human and mouse colon cancer cells due to the inhibition of FOXM1 by TST.
[0185] The in vitro cytotoxicity of TST against MC38 cancer cells and SMC normal cells was tested. The median inhibitory concentration (IC10) of TST. 50 The concentration was 3.8 μM in MC38 cancer cells, whereas, in contrast, no significant apoptosis was observed in SMC normal cells. Flow cytometry analysis showed that TST treatment significantly increased apoptosis in MC38 cancer cells (Fig. 11e).
[0187] Example 8: Confirmation of the antitumor effect of ThioLipo
[0188] 8.1. Preparation and Characterization of ThioLipos
[0189] (1) Method for manufacturing ThioLipos
[0190] Cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2-disteroyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000](DSPE-PEG2000) were purchased from Avanti Polar Lipids (Alabama, USA). DOPC, cholesterol, and DSPE-PEG2000 were added to a round-bottom flask in molar ratios of 55, 40, and 5, respectively. TST was dissolved in chloroform at a concentration of 1.5 mg / mL, and 1 mL of the solution was added to the lipid sample. The solution was dried using a rotary evaporator to leave a thin lipid film. 1 mL of PBS was added to the round-bottom flask, and the sample was sonicated in a Bath sonicator at 25°C for 5 minutes. After removing lipids from the flask, the solution was transferred to a dram vial and sonicated for 20 minutes using a probe sonicator. Uncaptured TST and other impurities were removed by centrifugation at 600 ×g for 5 minutes at 25 °C. Free TST was further removed using a PD-10 size exclusion column. The size distribution (Z-mean) and polydispersity index were characterized using dynamic light scattering (DLS; Malvern Zetasizer). The concentration of TST encapsulated in nanoliposomes was analyzed by dissolving the nanoliposomes in DMSO and measuring the absorbance at 300 nm using a UV-Vis spectrophotometer (DU730, Beckman Coulter, Brea, CA). For transmission electron microscopy (TEM) of ThioLipos, a grid (Quantifoil, R1.2 / 1.3, 200 mesh, EMS) with a hydrophilic surface was prepared using a glow discharge system (PELCO easiGlow, Ted pella), 4 μL of sample was added to the grid and blotted for 1.5 seconds at 100% humidity and 4°C, respectively.Subsequently, the samples were quenched and frozen to vitrify them in liquid ethane using Vitrobot Mark IV (FEI). The samples were analyzed at the Nano-Bioimaging Center (Seoul National University, Korea) using Talos L120C (FEI) at 120 kV.
[0191] (2) Characterization of ThioLipos
[0192] TST is a hydrophobic compound with low water solubility, and liposome encapsulation was adopted as a system to effectively deliver this hydrophobic drug to tumors (Fig. 12a). The hydrodynamic size of the prepared ThioLipos was 192 nm, and TEM images of the ThioLipos showed a rounded monolayer structure (Fig. 12c). The stability of the ThioLipos was also tested. There was no significant change in the size distribution over 15 days (Fig. 12d). The encapsulation efficiency of TST in nanoliposomes was 63±3%, and the TST-to-lipid ratio in nanoliposomes was 0.37±0.018.
[0193] In addition, we investigated whether the blood concentration of TST could be enhanced in vivo using the ThioLipos form. Due to the hydrophobic nature of TST, free TST was injected intraperitoneally, while LipoThio was injected intravenously. Since sensitive methods for detecting TST in blood and other tissues have not been established, TST concentrations were analyzed using a TripleTOF5600 equipped with ultra-high performance liquid chromatography. Mice treated with ThioLipo showed significantly higher blood TST concentrations after 24 hours (Fig. 13).
[0195] 8.2. Verification of ThioLipo Effects
[0196] (1) Winter colorectal cancer model
[0197] All animal experiments were approved by the Institutional Animal Care and Use Committee of the National Cancer Center (NCC-21-615). MC38 cells (5 × 10⁶) were placed on the right side of C57BL / 6 mice (6 weeks old; Orient Bio, South Korea). 5 cells) were injected subcutaneously. The tumor size was approximately 150 mm 3 When [date] was reached, mice were randomly assigned to treatment groups. Mice were treated with anti-4-1BB (10 mg / kg, n = 10) and anti-PD-1 (10 mg / kg, n = 9) antibodies via intraperitoneal injection on days 0 and 2. ThioLipo was administered intravenously via tail vein on days 0 and 2 at a dose of 10 mg TST equivalent (equiv.) / kg (n = 11). Mice in the anti-4-1BB+ThioLipo group (n = 10) were treated with anti-4-1BB antibody (10 mg / kg, intraperitoneal injection) and Thio-Lipo (10 mg TST equivalent / kg, intravenous injection) on days 0 and 2, while mice in the anti-PD-1+ThioLipo group (n = 8) were treated with anti-PD-1 antibody (10 mg / kg, intraperitoneal injection) and Thio-Lipo (10 mg TST equivalent / kg, intravenous injection) on days 0 and 2. Control mice (n = 9) were intravenously injected with PBS solution (100 μL) on days 0 and 2. The antibodies and ThioLipos were administered a total of four times; tumor volume and body weight were measured daily until day 8, and tumor volume (V) was AB 2Calculated as / 2 (A and B represent the long and short diameters (mm), respectively). The antitumor synergy effect of combination therapy was determined by calculating the Drug Interaction Factor (CDI). The CDI was calculated using the following formula: CDI = AB / (A × B), where AB is the ratio of tumor size of the combination group to the control group, and A and B are the ratios of tumor size of the individual treatment groups to the control group. CDI values <1, <0.7, =1, and >1 represent synergy, significant synergy, additivity, and antagonism, respectively.
[0198] On day 8, mice were accommodated, and tumor tissues and normal vital organs (heart, lungs, kidneys, spleen, and liver) were collected and fixed in a 4% formaldehyde solution for immunohistochemical (IHC) and histopathological analysis. The tissues were paraffin-embedded, sectioned, and stained. Following standard procedures for DAB-chromomap discovery studies, IHC analysis of CD3 (1:150, ab16669; Abcam) and PD-L1 (1:100, #13684; Cell Signaling Technology) levels in tumor tissues from paraffin sections was performed using a Ventana Roche Discovery XT Immunostainer (Mannheim, Germany). Antigen retrieval was initiated by heat-induced unmarking of epitopes while the slides were immersed, in accordance with the manufacturer's instructions. Sections were incubated with the primary antibody at 37°C, followed by the application of the secondary antibody at room temperature. Detection was performed using the DAB chromomab detection kit according to the copper-enhanced diaminobenzidine development method, followed by light counterstaining with hematoxylin for 4 minutes. Subsequently, the sections were manually dehydrated, removed in xylene, and mounted on coverslips. Additionally, TUNEL (derminal deoxynucleotidyl transferase dUTP nick-end labeling) analysis was performed to evaluate apoptosis in the treated groups. Tissue sections were stained with hematoxylin and eosin (H&E) for histopathological analysis, and imaging of the stained tissue sections was performed using the Vectra Polaris system (Akoya Biosciences). Tissue sections were stained using the TUNEL analysis kit to analyze apoptosis in the normal tissues of the treated groups and compare it with the control group.
[0199] (2) Serum biochemical analysis
[0200] To analyze the potential toxicity of each treatment regimen, serum was collected from mice in each group on the last day of the experiment. Albumin (ALB), creatinine (CREA), total protein (TP), blood urea nitrogen (BUN), glucose (GLU), aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), creatine phosphokinase (CPK), total bilirubin (T-Bil), triglycerides (TG), phosphate (PHOS), calcium (CA), blood cholesterol (CHO) levels, and albumin / globulin ratio (A / G) were measured by TNPbio (Gwangju, Gyeonggi, Korea).
[0201] In all statistical analyses, differences between groups were evaluated using the Student's t-test. Statistical significance was set at P < 0.05, and data were expressed as mean ± standard error.
[0202] (3) Confirmation of efficacy of combination therapy with immune checkpoint inhibitors and ThioLipos
[0203] In a winter colorectal cancer model, the tumor size is 150 mm 3 Treatment was initiated on Day 0 when [date] was reached (Fig. 14a). ThioLipos was administered intravenously, and the antibody therapeutic was administered intraperitoneally. Each treatment group was treated with ThioLipo (10 mg TST equivalent / kg), anti-4-1BB antibody (10 mg / kg), or anti-PD-1 antibody (10 mg / kg). Treatment with anti-4-1BB antibody, anti-PD-1 antibody, or ThioLipo alone resulted in a reduction of tumor volume of 24% (p < 0.05), 39% (p < 0.05), and 31% (p < 0.05), respectively, compared to the control group (Figs. 14b and 14c).
[0204] In cases where the tumor size is small (80mm 3 While better treatment outcomes can be expected with single ICI therapy, to confirm the efficacy of combination therapy with ICI and ThioLipos in a rapidly growing tumor model, 150mm 3The experiment was started at tumor sizes. In particular, combination therapy with the anti-4-1BB+ThioLipo and anti-PD-1+ThioLipo groups exhibited an antitumor synergistic effect, showing tumor growth inhibition of 56% (p < 0.001) and 74% (p < 0.001), respectively, in tumor-bearing mice compared to the control group. The calculated CDI values for the anti-4-1BB+ThioLipo group and the anti-PD-1+ThioLipo group were 0.83 and 0.61, respectively, and no difference in body weight was observed between the treatment groups.
[0205] The enhanced therapeutic effect of ThioLipos was further analyzed by staining tumor sections using the TUNEL assay kit and IHC on day 8 (Fig. 15). Compared to the control group, apoptosis in the tumors increased 3.2-fold, 8.1-fold, and 7.7-fold in the ThioLipo-treated group (P < 0.05), the anti-4-1BB-treated group (p < 0.001), and the anti-PD-1-treated group, respectively. Apoptosis in the anti-4-1BB+ThioLipo and anti-PD-1+ThioLipo groups increased 2.4-fold and 2.7-fold, respectively, compared to the anti-4-1BB-treated group (p < 0.001) and the anti-PD-1-treated group (p < 0.01). IHC staining of tumor sections showed that CD3+ T cells increased 3.8-fold, 3.4-fold, and 4.7-fold in the ThioLipo-treated group (p < 0.01), the anti-4-1BB-treated group (p < 0.001), and the anti-PD-1-treated group (p < 0.001), respectively, compared to the control group. Tumor-infiltrating CD3+ T cells in the anti-4-1BB+ThioLipo and anti-PD-1+ThioLipo groups increased 2.3-fold and 3.4-fold, respectively, compared to the anti-4-1BB-treated group (P < 0.01) and the anti-PD-1-treated group (P < 0.001). In addition, IHC staining for PD-L1 protein was performed on tumor sections to measure changes in PD-L1 levels. As expected, PD-L1 levels in tumor sections were significantly downregulated in ThioLipo-treated tumors (47.7% inhibition compared to the control group, p < 0.001). PD-L1 levels in the combination therapy group were also significantly lower than those in the ICI-treated group. Although PD-L1 expression increased with anti-PD-1 treatment, combination therapy with anti-PD-1 antibodies and ThioLipos significantly inhibited PD-L1 levels in tumor tissue.
[0206] To identify the side effects of the treatment regimen on normal tissues of each treatment group in vivo, major organs (heart, spleen, lungs, kidneys, and liver) were collected and sectioned at the end of the experiment. H&E and TUNEL staining were performed on the tissue sections, and mouse blood samples were also collected and analyzed. As previously mentioned, no difference in body weight was observed between the treatment groups. TUNEL stained images of normal tissue sections did not show an increase in apoptosis in any of the treatment groups compared to the control group (Fig. 16a). Furthermore, no histopathological changes were observed in the H&E stained images of normal tissue sections. Serum biochemical analysis also showed no signs of toxic effects in the treatment groups compared to the control group (Fig. 16b).
[0208] Example 9: Confirmation of the effects of FDI-6 and RCM1 on lung cancer, colorectal cancer, and brain tumor cell lines
[0209] 9.1. Analysis of Apoptosis, Viability, and Protein Expression
[0210] (1) Reagents and cell cultures used in the experiment
[0211] Dimethyl sulfoxide (DMSO), FDI-6 (Sigma-Aldrich, St. Louis, MO, USA, CAS Number: 313380-27-7), RCM1 (R&D Systems, Minneapolis, MN 55413, USA, CAS No: 339163-65-4), Amicon centrifugal filter unit (MWCO 50 K, UFC805024, Merck Millipore), Sephadex G25 gel filtration column (PD-10; #17-0851-01, GE Healthcare), anti-PD-1 (clone: RMP1-14, BP0146), anti-4-1BB (clone: 17B5, BE0296) antibody (BioXcell), anti-CD3 antibody (ab16669, Abcam), anti-PD-L1 antibody (13684, Cell Signaling Technology).
[0212] Human lung cancer cell lines (H1299, PC9), colorectal cancer cell lines (HCT116, SW480), and brain tumor cell line (U118) were purchased from the American Type Culture Collection (Manassas, VA, USA). H1299, PC9, U118, and SW480 cells were cultured in RPMI (Roswell Park Memorial Institute) medium supplemented with 10% FBS and 1% penicillin / streptomycin, and HCT116 cells were cultured in McCoy's 5A medium supplemented with 10% FBS and 1% penicillin / streptomycin. Cells were maintained at 37°C in a humidified incubator with 5% CO2.
[0213] (2) Immunoblotting
[0214] For immunoblotting analysis, protein concentrations were measured using a viscinconinic acid kit (Cat. 23225; Thermo Fisher Scientific, Carlsbad, CA, USA), and proteins were separated by SDS-PAGE electrophoresis. Primary antibodies against FOXM1 (#ab207298, Abcam), PD-L1 (#14-5982-82, Invitrogen), and glyceraldehyde-3-phosphate dehydrogenase (#sc-25778, Santa Cruz Biotechnology) were added, and the samples were incubated overnight at 4°C. After washing, appropriate secondary antibodies conjugated with horseradish peroxidase were attached to the membrane, and protein bands were detected using a chemiluminescence kit (Thermo Fisher Scientific, Carlsbad, CA, USA).
[0215] (3) Analysis of PD-L1 expression in lung cancer cell lines following RCM1 treatment
[0216] To confirm the dose-dependent downregulation of PD-L1 expression by the FOXM1 inhibitor RCM1, live cell imaging of PD-L1 expression was performed in the lung cancer cell line H1299. H1299 cells were cultured in Lab-Tek II and treated with RCM1 (10 μM) for 48 hours. Subsequently, cells were cultured with an anti-PD-L1 antibody (#14-5982-82; eBioscience, San Diego, CA, USA) and then conjugated with a secondary antibody labeled Alexa Fluor 594 (A21209; Thermo Fisher, Waltham, MA, USA), and cell nuclei were stained with Hoechst 33342 dye (Thermo Fisher, Waltham, MA, USA). Cells were washed three times with PBS (pH 7.4, 10 mM, 136 mM NaCl), and the medium was replaced with fresh complete medium. Nuclei (λ ex 359 nm, λ em 457 nm) and PD-L1 (λ ex 590 nm, λ em Fluorescence images at 618 nm were obtained using a confocal scanning laser microscope (LSM780; Carl Zeiss, Oberkochen, Germany).
[0218] 9.2. Confirmation of the effects of FDI-6 and RCM1 on PD-L1 expression in lung, colorectal, and brain tumor cells
[0219] As a result of analyzing the effects of FDI-6 and RCM1 on PD-L1 expression in lung cancer, colorectal cancer, and brain tumor cell lines, treatment with FDI-6 in lung cancer cell line (PC9) and colorectal cancer cell line (SW480) significantly reduced both FOXM1 and PD-L1 expression (Figs. 17a and 17b). In addition, treatment with RCM1 in lung cancer cell line (H1299), colorectal cancer cell line (HCT116), and brain tumor cell line (U118) also significantly reduced FOXM1 and PD-L1 expression (Fig. 18a). Confocal fluorescence imaging analysis also confirmed that the level of PD-L1 expressed on the surface of cancer cells decreased after treatment with RCM1 (Fig. 18b). Just as FOXM1 selectively upregulates PD-L1 expression by directly binding to the nuclear PD-L1 promoter, it was confirmed that FOXM1 inhibitors FDI-6 and RCM1 reduce PD-L1 expression in human lung cancer, colorectal cancer, and brain tumor cells by inhibiting FOXM1.
[0221] From the foregoing description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as including all modifications or variations derived from the meaning and scope of the claims set forth below and their equivalents, rather than from the detailed description above.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of cancer comprising a FOXM1 (Forkhead box protein M1) inhibitor and an immune checkpoint inhibitor as active ingredients, wherein the FOXM1 inhibitor is thiostreptone, the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-4-1BB antibody, and the cancer is lung cancer or colorectal cancer. Claim 2 delete Claim 3 delete Claim 4 A pharmaceutical composition according to claim 1, wherein the composition reduces the expression of PD-L1. Claim 5 A pharmaceutical composition according to claim 1, wherein the FOXM1 inhibitor is carried in a liposome. Claim 6 In claim 1, the pharmaceutical composition is for the combined administration of a FOXM1 inhibitor and an immune checkpoint inhibitor. Claim 7 In claim 6, the pharmaceutical composition is in the form of a mixture of a FOXM1 inhibitor and an immune checkpoint inhibitor, or a pharmaceutical composition in which a FOXM1 inhibitor and an immune checkpoint inhibitor are each formulated and administered simultaneously or sequentially. Claim 8 delete Claim 9 An anticancer adjuvant comprising a FOXM1 (Forkhead box protein M1) inhibitor and an immune checkpoint inhibitor as active ingredients, wherein the FOXM1 inhibitor is thiostreptone, the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-4-1BB antibody, and the cancer is lung cancer or colorectal cancer. Claim 10 delete Claim 11 delete
Citation Information
Patent Citations
FOXM1 inhibitor compositions and methods of using same
JP2021521164A
PD-1 / PD-L1 inhibitors
KR1020200145834A
PD-1 / PD-L1 inhibitors
KR1020210031936A
JP06470184B2
